Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
![](https://pharmashots.com/wp-content/uploads/2020/10/Press-Release-300x161.png)
- Oral Session:?652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
- Date:?Monday, December 7, 2020,?2:30 p.m. Eastern Standard Time
- The induction of an activated profile in NK cells by NKTR-255 results in an effective enhancement of their anti-myeloma effector function in?ex vivo?assays.
- In vivo?studies confirmed superiority of the combination of daratumumab and NKTR-255 compared to single agents in controlling MM growth.
- NKTR-255 improves the immune cell compartment both in the tumor tissue and blood following anti-CD38 treatment.
- Poster Session:?203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I
- Date:?Saturday, December 5, 2020,?7:00 a.m.???3:30 p.m. Eastern Standard Time
- NKTR-255 significantly enhanced the?in vitro?cytotoxicity of expanded NK cells when combined with rituximab against MEC-1, PGA-1, and DOHH2 as compared to the control groups.
- NKTR-255 also significantly enhanced the?in vitro?cytotoxicity of expanded NK cells when combined with obinutuzumab against rituximab-resistant BL cells like Raji-2R and Raji-4RH as compared to the control groups.
- NKTR-255 significantly enhanced the ADCC of expanded NK cells with anti-CD20 type I and type II antibodies against CLL, FL and rituximab-resistant BL cells in vitro with enhanced IFN-?, granzyme B and perforin release.
Jerry Isaacson?of Nektar Therapeutics
628-895-0634
Vivian Wu?of Nektar Therapeutics
628-895-0661 For Media:
Dan Budwick?of 1AB
973-271-6085
dan@1abmedia.com 1.? Blood 2018?Jun 7;131(23):2515-2527 SOURCE Nektar Therapeutics
![](https://rt.prnewswire.com/rt.gif?NewsItemId=SF15498&Transmission_Id=202012071600PR_NEWS_USPR_____SF15498&DateId=20201207)